Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 21Terminated 4Active not recruiting 4Recruiting 2Withdrawn 1Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 33Other solid neoplasm 6Gastrointestinal 2Tumor-Agnostic 1Head & Neck 1Gynecologic 1CNS 1

Conditions

Uterine Cervical Neoplasms 1

Interventions

Paclitaxel 20Carboplatin 20Bevacizumab 13Radiotherapy 12Cisplatin 11Cyclophosphamide 8olaparib 6niraparib 6Taxes 6pembrolizumab 5Magnetic Resonance Spectroscopy 5Gemcitabine 5Biopsy 5talazoparib 4dostarlimab 4aldesleukin 4Specimen Handling 4Fulvestrant 4Doxorubicin 4fludarabine 3atezolizumab 3Topotecan 3Radiation 3NVP-BKM120 3Methods 3Metformin 3Letrozole 3Hyperthermic Intraperitoneal Chemotherapy 3Early Intervention, Educational 3Colposcopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Pemetrexed × Gynecologic × Clear all
NCT04943627 2022-10-05

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Agenus Inc.

Phase 3 Withdrawn
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡